Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins.

Learn about applications
View all Applications
Resources Investors Careers News About Store Community Contact

Joshua B. Edel

Multiplexed detection of soluble proteins and other biomarkers in unprocessed clinical samples

About Joshua B. Edel

Joshua Edel is professor of biosensing and analytical sciences within the department of chemistry at Imperial College London. He is an expert in the development of trace analyte analytical platforms including bioanalytical sensors for use with clinical samples. He has published over 150 research articles and has given more than 140 invited talks. In 2011 he was awarded a prestigious ERC StG grant on rare event bioanalysis and in 2017 he was awarded an ERC Consolidator award related to the development of selective single-molecule biosensors. Prof. Edel has pioneered techniques such as high-throughput droplet microfluidics (Nature Chemistry [2011]), optical and electrical single-molecule sensors (Nature Communications [2017, 2019]), plasmonic nanopore sensors (Nano Letters [2015]), self-assembly at immiscible interfaces (Nature Materials [2013, 2017]), and nanoscale probes(Nature Nanotechnology [2019]). Prof. Edel has been funded by organizations such as EPSRC, ERC, Wellcome Trust, British Heart Foundation, DstL, CRUK, BBSRC, as well as industrial partners and actively acts as a consultant in biosensing.


There is an enormous need for analytical methods that can achieve simultaneous detection of multiple soluble proteins and other biomarkers in complex biological fluids. A technology that can achieve this holds the promise of far-reaching impact in multiple healthcare grand challenges both in point-of-care diagnostics and monitoring disease progression. We report on nanopore technology, developed by our teams in collaboration with Oxford Nanopore Technologies, to detect proteins and other biomarkers. The technology has the potential for multiplexed detection, directly in native clinical samples with no processing. The proposed platform will be able to detect serum biomarkers simultaneously, with high sensitivity, rapidly and offers great promise for the identification of diagnostic/prognostic biomarkers and validation of emerging biomarkers. We demonstrate the multiplexed label-free detection of soluble proteins and other biomarkers in biofluids using nanopores, via customisation and use of molecular probes, which can be used to confirm concentration and presence of a particular biomarker. Each probe contains an aptamer sequence for the detection of protein biomarkers or other biomarkers. Detection is validated in clinical samples from patients and control groups. Preliminary results using the technology indicate a significant advantage over existing techniques.

Joshua B. Edel

Joshua B. Edel

Open a chat to talk to our sales team